Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ARS Pharmaceuticals Securities Fraud...
Regulatory Securities Class Action

ARS Pharmaceuticals Securities Fraud Class Action

Analysis based on 62 articles · First reported Aug 06, 2026 · Last updated Aug 20, 2026

Sentiment
-40
Attention
2
Articles
62
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit could lead to financial liability for ARS Pharmaceuticals and may negatively affect investor confidence and the company's stock price. The allegations of misleading statements regarding neffy's insurance coverage could also impact the commercial prospects of the product and the company's reputation.

Pharmaceuticals Legal Services
Event Summary

Multiple law firms, including Bronstein, Gewirtz & Grossman, LLC, Rosen Law Firm, and Schall Brown & Schwartz LLP, have announced a securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain officers. The lawsuit alleges that between March 9, 2026 and June 24, 2026, the company made materially false and misleading statements regarding the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, through CVS Health. Specifically, defendants expressed confidence that coverage would begin on July 1, 2026, in time for summer and back-to-school allergy seasons, while allegedly concealing material adverse facts about potential delays. When the true details emerged, investors suffered damages. The class period is March 9, 2026 to June 24, 2026, and the deadline to seek lead plaintiff status is October 5, 2026. The lawsuit seeks to recover damages for investors who purchased ARS securities during the class period.

Key Actions
100 Rosen Law Firm filed class action ARS Pharmaceuticals
100 Bronstein, Gewirtz & Grossman, LLC filed class action ARS Pharmaceuticals
100 Schall Brown & Schwartz LLP filed class action ARS Pharmaceuticals
100 Faruqi & Faruqi filed securities class action ARS Pharmaceuticals
100 Levi & Korsinsky filed securities class action ARS Pharmaceuticals
100 Kaplan Fox & Kilsheimer filed class action ARS Pharmaceuticals
92 ARS Pharmaceuticals disclosed zero additions
90 CVS Health reserved coverage decision ARS Pharmaceuticals
90 ARS Pharmaceuticals announced no expanded coverage CVS Health
80 Pomerantz LLP filed class action ARS Pharmaceuticals
70 William Blair & Company lowered estimates ARS Pharmaceuticals
Entities Involved
priv
ARS Pharmaceuticals
ARS Pharmaceuticals is the defendant in the securities class action, facing allegations of misleading investors about neffy's insurance coverage timeline. The lawsuit could result in financial damages and reputational harm.
Importance 100.0 Sentiment -60.0
stock
CVS Health
CVS Health is central to the allegations as the insurance coverage timeline for neffy through CVS Health was the subject of the alleged misleading statements. The company is not a defendant but its formulary decisions are under scrutiny.
Importance 70.0 Sentiment -10.0
priv
Rosen Law Firm
Rosen Law Firm is another law firm that announced the class action and is seeking lead plaintiff. The firm stands to gain from successful litigation and investor compensation.
Importance 60.0 Sentiment 20.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is one of the law firms that announced the class action and is representing investors on a contingency fee basis. The firm benefits from potential recovery and increased visibility.
Importance 60.0 Sentiment 20.0
priv
Schall Brown & Schwartz LLP
Schall Brown & Schwartz LLP is also involved in the class action, encouraging shareholders to contact the firm. The firm benefits from potential recovery and client acquisition.
Importance 50.0 Sentiment 20.0
govactor
United States — United States Securities and Exchange Commission
The SEC is referenced as the regulatory body under whose rules the lawsuit is brought (Rule 10b-5). The SEC itself is not a party but the case highlights potential regulatory scrutiny of ARS Pharmaceuticals' disclosures.
Importance 30.0 Sentiment 0.0
per
Lawrence Rosen
Lawrence Rosen is the founding partner of Rosen Law Firm and is involved in the class action. His firm's reputation and experience are leveraged in the litigation.
Importance 30.0 Sentiment 10.0
per
Peretz Bronstein
Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC and is a contact for the class action. His role is to represent investors and seek recovery.
Importance 30.0 Sentiment 10.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm and a contact for investors. He plays a role in the class action process.
Importance 20.0 Sentiment 10.0
per
Brian Schall
Brian Schall is a founding partner of Schall Brown & Schwartz LLP and is a contact for the class action. He represents investors in the litigation.
Importance 20.0 Sentiment 10.0
per
David Schwartz (disambiguation)
David Schwartz (disambiguation) is a founding partner of Schall Brown & Schwartz LLP and is a contact for the class action. He represents investors in the litigation.
Importance 20.0 Sentiment 10.0
per
Nathan Miller
Nathan Miller is the Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, serving as a contact for investors. His role is administrative and supportive to the litigation.
Importance 10.0 Sentiment 5.0
Relationships
Rosen Law Firm co-counsel ↔ Bronstein, Gewirtz & Grossman, LLC Rosen Law Firm frequently collaborates with Bronstein, Gewirtz & Grossman, LLC as co-counsel on investor-rights class ac
Rosen Law Firm co-plaintiff ↔ Schall Brown & Schwartz LLP Rosen Law Firm frequently collaborates with Schall Brown & Schwartz LLP as co-counsel or co-plaintiff in securities clas
Rosen Law Firm securities litigator ↔ United States — United States Securities and Exchange Commission Rosen Law Firm is a global investor rights law firm specializing in filing class action lawsuits against companies for a
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Peretz Bronstein
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Brian Schall
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Schall Brown & Schwartz LLP Bronstein, Gewirtz & Grossman, LLC and Schall Brown & Schwartz LLP frequently act as co-plaintiffs or pursue parallel le
Bronstein, Gewirtz & Grossman, LLC securities litigator ↔ United States — United States Securities and Exchange Commission Bronstein, Gewirtz & Grossman, LLC is a law firm whose business model relies on the federal securities laws and regulati
Bronstein, Gewirtz & Grossman, LLC related ↔ Lawrence Rosen
Bronstein, Gewirtz & Grossman, LLC related ↔ Peretz Bronstein
Bronstein, Gewirtz & Grossman, LLC related ↔ Philip Kim
Bronstein, Gewirtz & Grossman, LLC related ↔ Brian Schall
Schall Brown & Schwartz LLP plaintiff counsel ↔ United States — United States Securities and Exchange Commission Schall Brown & Schwartz LLP is a law firm specializing in securities class action lawsuits, representing investors under
Schall Brown & Schwartz LLP related ↔ Lawrence Rosen
+ 13 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.